Biontech takes over Curevac: Tübingen becomes the center of mRNA research!

Biontech takes over Curevac: Tübingen becomes the center of mRNA research!

Tübingen, Deutschland - Curevac, the Tübingen biotech company, has caused a lot of sensation in recent years, in particular through its developments in the field of mRNA technology. On June 12, 2025, the course was now set for a significant takeover: Biontech SE plans to buy Curevac for around $ 1.25 billion. Biontech boss Ugur Sahin announced this after visiting the Tübingen location. Sahin was impressed by the achievements of the past 25 years, which have made the location a central player in the MRNA sector. Over 80 percent of the approximately 700 employees work directly at the headquarters in Tübingen, which is to play an even more important role within the Biontech Group by taking over.

The purchase price is given at around $ 5.46 per curevac share, which reflects a healthy assessment of the company. Biontech plans to integrate curevacs mrNA technology and oncology programs into its own research landscape. The Federal Government has already signaled its support for this billion-dollar deal, which should not only strengthen Biontech's position on the market, but could also mix up the entire biotech segment.

strategic expansion in the mRNA area

The acquisition is expected to be completed in the fourth quarter of 2025 if all regulatory permits are granted. Curevacs CEO, Alexander Zehnder, is optimistic: "The merger opens up new opportunities for RNA innovations." In addition, the takeover brings almost 400 researchers and several promising MRNA development programs to the Biontech pipeline.

A look into the future

Biontech strives to submit a first application for admission for cancer treatment in the United States by the end of 2025. This therapy uses antibody-active ingredients to treat cancer cells-a strategy that has also been researched at Curevac in recent years. Despite the withdrawal of a candidate for vaccine due to less effectiveness, the Tübingen research center of Curevac is preserved, which is of great importance for the Region.

In addition, Biontech recently announced a cooperation with Bristol Myers Squibb to develop a cancer-active ingredient candidate. This cooperation is rewarded with $ 3.5 billion, with potential further payments of up to $ 7.6 billion.

With this takeover, an exciting chapter in the world of biotechnology is based, which brings with it both opportunities and challenges. While the stock prices were moderately reacted to, interest in innovative therapies is unbroken. Experts agree that Biontech-Curevac transaction sets a strong signal for the future of mRNA-based research and development and has the potential to change the industry sustainably.